1416P - Recurrence of infusion-related reaction (IRRs) associated to avimantamab

Background

Infusion-related reaction (IRR) are a common toxicty of amivantamab, with a high incidence during the first infusion (97%). However, subsequent injections are usually not affected, unless there is a delay in treatment for several weeks. We evaluate the risk of IRR after the resumption of amivantamab, based on the duration of the free treatment interval.

Methods

This was a retrospective observational study to evaluate the recurrence of IRR in advanced non-small cell lung cancer patients treated with amivantamab and lazertinib in Gustave Roussy (2019-2023).

Results

Baseline characteristics of patients are summarized in the table. 24 patients were included, 12 (50%) presented IRR during the first infusion, and only one of them presented previous history of allergy. 9 patients had a temporary discontinuation of treatment, but only 2 had an IRR recurrence (these 2 had experienced an IRR during first cycle). Median time of treatment discontinuation was of 25.57 days for those patients without IRR recurrence and 44 days for those who presented it. Both patients with IRR recurrence had a temporary withdrawal due to another toxicity (at day 29 and 59 respectively) being of CTCAE grade 3 and 2 respectively. 5 patients (41.6%) needed corticoesteroids and 6 (50%) received antihistamines as treatment for the IRR. Only one patient required magnesium sulfate. A third IRR recurrence was experienced in both patients (grade 2 and 1 respectively), leading to permanent treatment discontinuation for one patient. None of the patients progressed to amivantamab and both are still alive. Table: 1416P

Conclusions

Recurrence of IRR after the first episode is frequent and must be taken into account when reintroducing amivantamab after a temporary withdrawal of ≥1 month. IRR recurrence does not seem to have a detrimental impact on treatment efficacy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

J. Remon Masip: Financial Interests, Personal, Invited Speaker: Roche, MSD, Boehringer Ingelheim; Financial Interests, Personal, Writing Engagement: Pfizer; Financial Interests, Personal, Advisory Board: AstraZeneca, Ose Immunotherapeutics, BMS, Janssen, Takeda, Sanofi; Financial Interests, Institutional, Invited Speaker: Merck Portugal; Non-Financial Interests, Principal Investigator, PI of PECATI trial in Thymic malignancies endorsed by a grant by MSD: MSD; Non-Financial Interests, Other, Co-PI of APPLE trial (EORTC-1525): AstraZeneca; Non-Financial Interests, Member, Secretary of the Lung Cancer Group at the EORTC: EORTC. A. Gazzah: Non-Financial Interests, Advisory Board: AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, Roche; Financial Interests, Advisory Board: Novartis, Sanofi , Roche, Pfizer, Novartis, Boehringer Ingelheim; Financial Interests, Principal Investigator: Amgen, Astex, Argen-X Byba, Bristol Myer Squibb, Celegne, Gilead, Lilly, Novartis, Pharma Mar, Pierre Fabre, Merck Sharp. P. Lavaud: Financial Interests, Advisory Board: Astellas, AstraZeneca, Janssen, Sanofi; Non-Financial Interests, Advisory Board: AstraZeneca, Hoffman-La Roche; Other: Astellas. A. Levy: Financial Interests, Institutional, Invited Speaker: Pharma Mar; Financial Interests, Institutional, Funding: AstraZeneca; Financial Interests, Institutional, Coordinating PI: BeiGene. S. Ponce Aix: Financial Interests, Advisory Board: BMS, MSD, Roche, AstraZeneca, Takeda. F. Barlesi: Financial Interests, Institutional, Advisory Board: AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, Mirati, MSD, Pierre Fabre, Pfizer, Sanofi Aventis, Seattle Genetics, Takeda, AbbVie, Acea, Amgen, Eisai, Ignyta; Non-Financial Interests, Principal Investigator: AstraZeneca, BMS, Merck, Pierre Fabre, F. Hoffmann-La Roche Ltd., Innate Pharma, Mirati. D. Planchard: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche, Samsung, Celgene, AbbVie, Daiichi Sankyo, Janssen, Seagen, Gilead, Pierre Fabre; Financial Interests, Personal, Invited Speaker: AstraZeneca, Novartis, Pfizer, priME Oncology, Peer CME, Samsung, AbbVie, Janssen; Non-Financial Interests, Principal Investigator, Institutional financial interests: AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche, Daiichi Sankyo, Sanofi-Aventis, Pierre Fabre; Non-Financial Interests, Principal Investigator: AbbVie, Sanofi, Janssen. B. Besse: Financial Interests, Institutional, Funding: 4D Pharma, AbbVie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Celgene, Cergentis, Cristal Therapeutics, Daiichi Sankyo, Eli Lilly, GSK, Janssen, Onxeo, Ose Immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals; Financial Interests, Institutional, Research Grant: Chugai Pharmaceutical, Eisai, Genzyme Corporation, Inivata, Ipsen, Turning Point Therapeutics. All other authors have declared no conflicts of interest.